cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Erasca Inc
1 own
1 watching
Current Price
$3.91
$0
(0%)
logo-eras
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
473.21M
52-Week High
52-Week High
12.8
52-Week Low
52-Week Low
3.6
Average Volume
Average Volume
0.58M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization473.21M
icon52-Week High12.8
icon52-Week Low3.6
iconAverage Volume0.58M
iconDividend Yield--
iconP/E Ratio--
What does the Erasca Inc do?
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Read More
How much money does Erasca Inc make?
News & Events about Erasca Inc.
Globe Newswire
23days ago
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 41st annual J...
Zolmax
1month ago
Erasca, Inc. (NASDAQ:ERAS Get Rating) Director Bihua Chen bought 307,692 shares of the firms stock in a transaction that occurred on Tuesday, December 13th. The stock was purchased at an average cost of $6.50 per share, with a total value of $1,999,998.00. Following the completion of the transaction...
Globe Newswire
1month ago
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support combination development BRAF Class 2 and 3 alterations have no approved targeted therapies and ...
Market News Video
1month ago
In trading on Monday, shares of Erasca Inc (ERAS) touched a new 52-week low of 4.34/share. Thats a 11.66 share price drop, or -72.88% decline from the 52-week high of 16.00 set back on 12/31/2021...
Globe Newswire
1month ago
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and ...
Frequently Asked Questions
Frequently Asked Questions
What is Erasca Inc share price today?
plus_minus_icon
Can Indians buy Erasca Inc shares?
plus_minus_icon
How can I buy Erasca Inc shares from India?
plus_minus_icon
Can Fractional shares of Erasca Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Erasca Inc stocks?
plus_minus_icon
What is today’s traded volume of Erasca Inc?
plus_minus_icon
What is today’s market capitalisation of Erasca Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Erasca Inc?
plus_minus_icon
What percentage is Erasca Inc down from its 52-Week High?
plus_minus_icon
What percentage is Erasca Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.91
$0
(0%)
logo-eras
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00